Bioline Rx reported $4.63M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Arca Biopharma USD 191.52M 76.95M Sep/2026
Bio Path 13.65M 3.37M Sep/2022
Bioline Rx USD 4.63M 2.12M Jun/2026
Capricor Therapeutics USD 44.28M 23.34M Sep/2026